je.st

Home › advanced

Tag: advanced

Relay test software offers many advanced features

2016-09-30 20:07:25| Canadian Plastics Headlines

Meggers Relay Test and Management Software is designed to manage protective relay testing using the Megger SMRT family. It comes with many advanced featur The post Relay test software offers many advanced features appeared first on Canadian Plastics.

Tags: software advanced features test

UPS places 50 advanced hydraulic hybrids in its fleet in time for holiday rush

2016-09-30 10:55:29| Green Car Congress

Tags: time advanced places holiday

UK MoD grants licence to ASV Global to use its advanced USV capability technology

2016-09-30 01:00:00| Naval Technology

The UK Ministry of Defence (MoD) has granted a licence to ASV Global to use its advanced unmanned surface vehicle (USV) capability technology.

Tags: advanced technology global mod

Two New Trials of Mercks KEYTRUDA (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016

2016-09-28 12:45:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Results from KEYNOTE-024, which Studied KEYTRUDA Compared to Chemotherapy in Patients with High Levels of PD-L1 Expression, and KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone in Patients Regardless of PD-L1 Expression, to be Presented Comprehensive Data from Mercks Industry-Leading Immuno-Oncology Clinical Development Program to be Presented, with New Data in 12 Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 11. In total, findings from 30 studies in 12 cancers from Mercks industry-leading clinical development program for KEYTRUDA both as monotherapy and in combination will be presented at this years ESMO. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to advanced presented cell